Fund Details
Overview
Investment portfolio
12rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Allogenetics | Sep 2026Participated | $4 MSeries A | |
Kupando | Mar 2026Participated | $12 MSeries A | |
Exciva | Jan 2026Participated | $60 MSeries B | |
TECregen | Jan 2026Participated | $13 MSeed | |
Akribion Therapeutics | Feb 2025Led | $9 MSeed | |
Aignostics | Oct 2024Participated | $34 MSeries B | |
Symphera | Sep 2024Participated | $3 MSeed | |
Thryve | Aug 2024Participated | $5 MSeries A | |
Heidelberg Epignostix | Jul 2024Led | $5 MSeed | |
Acorai | Jan 2024Participated | $5 MSeed | |
inContAlert | Sep 2023Led | $2 MSeed | |
Aignostics | Sep 2022Participated | $14 MSeries A | |
Allogenetics | Sep 2026Participated | $4 MSeries A | |
Kupando | Mar 2026Participated | $12 MSeries A | |
Exciva | Jan 2026Participated | $60 MSeries B | |
TECregen | Jan 2026Participated | $13 MSeed | |
Akribion Therapeutics | Feb 2025Led | $9 MSeed | |
Aignostics | Oct 2024Participated | $34 MSeries B | |
Symphera | Sep 2024Participated | $3 MSeed | |
Thryve | Aug 2024Participated | $5 MSeries A | |
Heidelberg Epignostix | Jul 2024Led | $5 MSeed | |
Acorai | Jan 2024Participated | $5 MSeed | |
inContAlert | Sep 2023Led | $2 MSeed | |
Aignostics | Sep 2022Participated | $14 MSeries A |
12 Items
12
Items
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 3 | 3 |
| Series A | 0 | 4 |
| Series B | 0 | 2 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Sep '22 | 1 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 1 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 1 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 1 |
| Aug '24 | 1 |
| Sep '24 | 1 |
| Oct '24 | 1 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 1 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 2 |
| Feb '26 | 0 |
| Mar '26 | 1 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 1 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 12 |
| Manufacturing | 3 |
| AI & Machine Learning | 3 |
| Consumer & Lifestyle | 2 |
| Hardware & Robotics | 1 |
| Developer Tools | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 6 |
| $5M-$10M | 1 |
| $10M-$25M | 3 |
| $25M-$50M | 1 |
| $50M-$100M | 1 |
| $100M-$250M | 0 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 1 of 1 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| Europe | 12 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| High-Tech Grunderfonds | 8 |
| Boehringer Ingelheim | 3 |
| IBB Ventures | 3 |
| Bayern Kapital | 2 |
| Mayo Clinic | 2 |
| Wellington Partners | 2 |
| Andera Partners | 1 |
| ATHOS | 1 |
| Bayer | 1 |
| Brandenburg Kapital | 1 |
| Bruker | 1 |
| Capricorn Venture Partners | 1 |
| Cedars-Sinai | 1 |
| CRB Health Tech | 1 |
| Eos Bioinnovation | 1 |
| EQT Life Sciences (LSP) | 1 |
| Fountain Healthcare Partners | 1 |
| Gimv | 1 |
| Hessen Kapital | 1 |
| IRCAD | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 3 | 25% |
| Participating | 9 | 75% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 1 | 33% |
| Co-led | 2 | 67% |